PAVmed (PAVM)

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome. Another key product is the EsoCheck Esophageal Cell Collection Device, which consists of a diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux, or simply reflux, in patients. Additionally, there is EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE, PortIO, an implantable intraosseous vascular access device, and the Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.